In vivo Gene Editing for sickle cell disease (Vertex Pharmaceuticals)

N/A

Report date: 2025/12/25 11:27:33

Base Information

Drug NameIn vivo Gene Editing for sickle cell disease (Vertex Pharmaceuticals)
Drug Alias NameIn vivo Gene Editing for SCD(Vertex Pharmaceuticals)
ClassificationCell and gene therapy > Gene therapy > Gene editing
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsAnemia, Sickle Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVertex Pharmaceuticals Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesVertex Pharmaceuticals Gmbh
Inactive CompaniesN/A
Active IndicationsAnemia, Sickle Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A